Top Markets
#1 Celer Network Celer Network +49.10%
#2 Gravity Gravity +24.44%
#3 Galxe Galxe +23.88%
#4 ICON ICON +13.39%
#5 MemeCore MemeCore +13.25%
#6 Cartesi Cartesi +12.87%
#7 Zilliqa Zilliqa +10.95%
#8 Genius Genius +10.65%
#9 Ontology Gas Ontology Gas +9.33%
#10 CyberDEX CyberDEX +7.13%
Coin of the day
Celer Network Celer Network
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Fusion Antibodies plc Fusion Antibodies plc

Fusion Antibodies plc

FAB
Kedudukan dalam Saham #40225
Fusion Antibodies plc operates as a contract research organization (CRO),... Fusion Antibodies plc operates as a contract research organization (CRO), providing specialized services in the research, development, and manufacturing of recombinant proteins and antibodies. The company primarily focuses on solutions for oncology and infectious diseases, serving a global clientele across the United Kingdom, broader Europe, and North America. Its comprehensive suite of offerings encompasses monoclonal antibody discovery and advancement, antibody sequencing and engineering, and a distinct platform for antibody humanization and rational affinity maturation. Additionally, Fusion Antibodies provides recombinant protein expression, stable cell line development, and cGMP-compliant scale-up services. Clients span the pharmaceutical, biotechnology, and diagnostic sectors. Notably, the company maintains a collaborative partnership with Celonic AG. Established in 2000, Fusion Antibodies plc is headquartered in Belfast, United Kingdom.
Harga Saham
$0.1559364
Disegerakkan terakhir: 2026-09-18
Modal Pasaran
$195.17K
Perubahan (1 hari)
6.60%
Perubahan (1 tahun)
-30.91%
Negara
GB
Perdagangan Fusion Antibodies plc (FAB)

Kategori

Healthcare
Hasil untuk Fusion Antibodies plc (FAB)
Hasil pada Sep 2025 TTM: $2.15M
Menurut laporan kewangan terkini daripada Fusion Antibodies plc, hasil semasa syarikat (TTM) ialah $2.15M. Pada tahun 2024, syarikat memperoleh hasil sebanyak $1.43M penurunan berbanding hasil pada tahun 2023 iaitu $3.58M. Hasil ialah jumlah pendapatan keseluruhan yang dijana oleh syarikat daripada jualan barangan atau perkhidmatan. Tidak seperti keuntungan, tiada perbelanjaan ditolak.
Sejarah hasil bagi Fusion Antibodies plc dari 2013 hingga 2026
Hasil pada akhir setiap tahun
Tahun Hasil Ubah
2026 (TTM) $2.15M -15.49%
2025 $2.54M 77.00%
2024 $1.43M -59.95%
2023 $3.58M -43.24%
2022 $6.31M 9.89%
2021 $5.74M 18.80%
2020 $4.83M 70.09%
2019 $2.84M -24.66%
2018 $3.77M 57.07%
2017 $2.40M 12.81%
2016 $2.13M 57.86%
2015 $1.35M 11.90%
2014 $1.20M 95.78%
2013 $615.46K 0.00%
Hasil untuk syarikat atau pesaing serupa
Syarikat Hasil Perbezaan Hasil Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B 588,305.51%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B 280,545.95%
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B 103,744.77%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B 733,726.73%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH